2022 World Conference on Lung Cancer (ePosters)-EP08.01-094. A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)

EP08.01-094. A Phase II Study of Camrelizumab combined with Apatinib and Albumin Paclitaxel in Advanced Non-squamous NSCLC (CAPAP-lung)

Back to course

Pdf Summary

In a phase II clinical study, researchers evaluated the combination of camrelizumab, apatinib, and albumin paclitaxel as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC). The study aimed to determine the efficacy and safety of this combination regimen.<br /><br />The study included patients with histologically or cytologically confirmed adenocarcinoma of the lung who were unable to undergo radical surgery or concurrent radiotherapy and had not received previous systemic treatment. The patients also had an ECOG score of 0-1 and a measurable lesion according to RECIST1.1 criteria. Patients with EGFR and ALK sensitive mutations were excluded from the study.<br /><br />The treatment regimen consisted of camrelizumab administered at a dose of 200mg every 3 weeks, apatinib at a dose of 250mg once daily, and albumin paclitaxel at a dose of 135mg/m2 on days 1 and 8 of a 3-week cycle for 4-6 cycles. Dose adjustments could be made based on toxicity.<br /><br />The primary endpoint of the study was progression-free survival (PFS), and secondary endpoints included overall survival (OS), duration of response (DOR), objective response rate (ORR), disease control rate (DCR), and quality of life (QoL).<br /><br />Out of the 60 patients enrolled in the study, 52 were evaluable for analysis. The combination regimen showed promising antitumor activity, with an objective response rate of 73.1% and a disease control rate of 98.1%. The median PFS was 10.97 months.<br /><br />The incidence of grade 3 or worse treatment-related adverse events was acceptable, with 31.6% of patients experiencing grade 3 events. The most common grade 3 adverse events were decreased neutrophil count, liver function damage, rash, and decreased white blood cell count.<br /><br />In conclusion, the combination of camrelizumab, apatinib, and albumin paclitaxel demonstrated encouraging antitumor activity and an acceptable safety profile as a first-line treatment for advanced non-squamous NSCLC. This study suggests that this combination regimen may be a potential treatment option for patients with advanced lung adenocarcinoma.

Asset Subtitle

Lin Wu

Meta Tag

Speaker Lin Wu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

phase II clinical study

camrelizumab

apatinib

albumin paclitaxel

first-line treatment

advanced non-squamous NSCLC

efficacy

safety

antitumor activity

lung adenocarcinoma